ABG Innovation Capital Partners III’s Whitehawk Therapeutics WHWK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-26,666
Closed -$64.5K – 1
2025
Q4
$64.5K Hold
26,666
– – 100% 1
2025
Q3
$50.7K Hold
26,666
– – 100% 1
2025
Q2
$49.9K Hold
26,666
– – 100% 1
2025
Q1
$47.5K Hold
26,666
– – 5.93% 2
2024
Q4
$84.1K Hold
26,666
– – 7.77% 2
2024
Q3
$54.9K Hold
26,666
– – 4.89% 2
2024
Q2
$38.9K Hold
26,666
– – 4.53% 2
2024
Q1
$62.4K Hold
26,666
– – 7.5% 2
2023
Q4
$53.9K Hold
26,666
– – 5.99% 2
2023
Q3
$129K Hold
26,666
– – 17.55% 2
2023
Q2
$182K Hold
26,666
– – 24.91% 2
2023
Q1
$193K Hold
26,666
– – 17.76% 2
2022
Q4
$342K Hold
26,666
– – 26.12% 2
2022
Q3
$377K Hold
26,666
– – 25.56% 2
2022
Q2
$329K Hold
26,666
– – 24.48% 2
2022
Q1
$453K Hold
26,666
– – 30.96% 3
2021
Q4
$644K Hold
26,666
– – 37.25% 1
2021
Q3
$783K Sell
26,666
-1
-0% -$30 32.53% 1
2021
Q2
$676K Hold
26,667
– – 2.26% 4
2021
Q1
$516K Hold
26,667
– – 0.25% 5
2020
Q4
$392K Buy
+26,667
New +$570K 0.23% 5

Other funds holding WHWK

ABG Innovation Capital Partners III's WHWK Position: Q1 2026 in Review

ABG Innovation Capital Partners III sold out of Whitehawk Therapeutics (WHWK) in Q1 2026, closing a stake of 26,666 shares — an estimated $64.5K sold.

ABG Innovation Capital Partners III first reported a position in WHWK in Q4 2020 and held it in 21 quarters. The position peaked at $783K in Q3 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • ABG Innovation Capital Partners III reported no remaining Whitehawk Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ABG Innovation Capital Partners III sold 26,666 Whitehawk Therapeutics shares in Q1 2026, an estimated $64.5K.
  • ABG Innovation Capital Partners III first reported a position in Whitehawk Therapeutics in Q4 2020 and held it in 21 quarters.
  • ABG Innovation Capital Partners III's Whitehawk Therapeutics position peaked at $783K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on ABG Innovation Capital Partners III's 13F filing for Q1 2026.